TRDA Entrada Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%
Returns
ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $905,000 | $898,000 | $875,000 | $1.30M | $1.61M | $1.95M | $20.56M | $37.40M |
| R&D expense | $32.37M | $35.37M | $33.05M | $33.96M | $38.36M | $37.88M | $32.07M | $33.41M |
| SG&A expense | $10.22M | $10.49M | $10.12M | $9.55M | $10.30M | $10.92M | $10.27M | $9.86M |
| Operating income | -$41.69M | -$44.96M | -$42.30M | -$42.21M | -$47.05M | -$46.85M | -$21.79M | -$5.87M |
| Income tax | $27,000 | $35,000 | $38,000 | $92,000 | $654,000 | $178,000 | $0 | -$1.87M |
| Net income | -$39.74M | -$42.76M | -$39.72M | -$39.16M | -$44.13M | -$43.10M | -$17.35M | $1.13M |
| EBITDA | -$40.99M | -$44.16M | -$41.50M | -$41.32M | -$45.85M | -$45.75M | -$20.84M | -$4.88M |
| EPS (basic) | -0.94 | -1.01 | -0.95 | — | -1.06 | -1.04 | -0.42 | — |
| EPS (diluted) | -0.94 | -1.01 | -0.95 | — | -1.06 | -1.04 | -0.42 | — |
| Weighted avg. shares (diluted) | 42.37M | 42.22M | 41.84M | — | 41.46M | 41.34M | 41.07M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $112.24M | $99.28M | $76.44M | $90.39M | $97.24M | $76.43M | $71.79M | $105.16M |
| Current assets | $202.95M | $232.70M | $266.87M | $306.25M | $338.26M | $369.15M | $403.19M | $440.04M |
| PP&E, net | $5.21M | $5.72M | $6.51M | $7.31M | $8.41M | $9.81M | $10.67M | $10.93M |
| Total assets | $266.88M | $298.88M | $335.52M | $377.38M | $412.90M | $448.78M | $486.48M | $526.32M |
| Current liabilities | $25.86M | $21.37M | $19.20M | $24.45M | $24.02M | $19.80M | $18.43M | $39.48M |
| Total liabilities | $68.56M | $65.47M | $64.66M | $71.25M | $72.18M | $69.28M | $69.22M | $97.64M |
| Shareholders' equity | $198.32M | $233.41M | $270.85M | $306.13M | $340.72M | $379.50M | $417.26M | $428.68M |
| Shares outstanding | 39.15M | 38.94M | 38.82M | 38.28M | 38.22M | 38.03M | 37.94M | 37.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$29.96M | -$32.46M | -$41.70M | -$32.20M | -$28.31M | -$29.49M | -$38.51M | -$31.61M |
| Capital expenditure | $161,000 | $11,000 | $44,000 | -$207,000 | -$171,000 | $275,000 | $1.14M | $635,000 |
| Free cash flow | -$30.12M | -$32.47M | -$41.74M | -$32.00M | -$28.14M | -$29.76M | -$39.65M | -$32.24M |
| Investing cash flow | $42.92M | $54.95M | $26.99M | $29.12M | $49.11M | $33.80M | $4.78M | $53.37M |
| Financing cash flow | $0 | $350,000 | $100,000 | $192,000 | $8,000 | $337,000 | $350,000 | $1.40M |
| Depreciation & amortization | $700,000 | $800,000 | $805,000 | $886,000 | $1.20M | $1.10M | $946,000 | $992,000 |
| Stock-based compensation | $4.78M | $5.15M | $4.74M | $4.36M | $5.12M | $5.05M | $5.09M | $4.70M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.